Published in J Clin Invest on October 01, 1993
Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol (1998) 8.74
Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A (1995) 3.85
KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol (2000) 2.99
Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci U S A (1997) 2.92
Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol (1999) 2.36
Mast cells and mastocytosis. Blood (2008) 2.32
Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci U S A (2003) 2.23
Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A (1999) 2.14
Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers. Cancer Res (2010) 2.06
Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood (2005) 1.83
Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol (2000) 1.79
One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol (2003) 1.72
Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med (1998) 1.70
mTOR regulates cell survival after etoposide treatment in primary AML cells. Blood (2005) 1.63
Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412. Blood (2005) 1.58
Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal. Am J Pathol (2000) 1.42
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol (2009) 1.42
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res (2009) 1.41
Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol (2003) 1.40
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res (2008) 1.39
KIT mutations are common in testicular seminomas. Am J Pathol (2004) 1.36
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood (2007) 1.33
Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling. Mol Cell Biol (2006) 1.33
Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol (2000) 1.28
IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm Res (2009) 1.27
Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders. Br J Pharmacol (2008) 1.25
The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells. Mol Cancer (2006) 1.25
Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. J Exp Med (2005) 1.18
Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood (2009) 1.16
Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol (2008) 1.15
Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One (2009) 1.14
Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. Proc Natl Acad Sci U S A (1996) 1.11
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med (2008) 1.10
Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc Natl Acad Sci U S A (2004) 1.10
The role of c-KIT in tumorigenesis: evaluation in canine cutaneous mast cell tumors. Neoplasia (2006) 1.09
Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol (2008) 1.09
Physical-chemical principles underlying RTK activation, and their implications for human disease. Biochim Biophys Acta (2011) 1.06
Inherited predisposition to myeloproliferative neoplasms. Ther Adv Hematol (2013) 1.06
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol (2009) 1.06
Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol Pathol (2000) 1.05
Further activation of FLT3 mutants by FLT3 ligand. Oncogene (2011) 1.04
Lipid rafts are required for Kit survival and proliferation signals. Blood (2007) 1.03
Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis (2005) 1.03
Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI. J Allergy Clin Immunol (2011) 1.02
Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line. Am J Pathol (1996) 1.01
Animal models of soft-tissue sarcoma. Dis Model Mech (2010) 1.01
Allelic heterogeneity at the equine KIT locus in dominant white (W) horses. PLoS Genet (2007) 1.01
Phenotypic and genotypic characteristics of mastocytosis according to the age of onset. PLoS One (2008) 0.98
Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig Dis Sci (2007) 0.98
Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5. J Exp Med (1994) 0.98
Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology (2003) 0.97
Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. Mol Cancer (2013) 0.96
Paediatric mastocytosis. Arch Dis Child (2002) 0.95
Pak and Rac GTPases promote oncogenic KIT-induced neoplasms. J Clin Invest (2013) 0.94
Mast cell homeostasis and the JAK-STAT pathway. Genes Immun (2010) 0.94
Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. Curr Genomics (2006) 0.93
Design and pharmacology of a highly specific dual FMS and KIT kinase inhibitor. Proc Natl Acad Sci U S A (2013) 0.91
Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms. PLoS Comput Biol (2011) 0.91
Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia. Mol Cancer (2013) 0.91
A novel FcεRIβ-chain truncation regulates human mast cell proliferation and survival. FASEB J (2010) 0.89
Molecular basis of CD36 deficiency. Evidence that a 478C-->T substitution (proline90-->serine) in CD36 cDNA accounts for CD36 deficiency. J Clin Invest (1995) 0.89
Comparative cytokine gene expression: regulation and release by human mast cells. Immunology (1998) 0.89
Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. Blood (2015) 0.88
Rational drug redesign to overcome drug resistance in cancer therapy: imatinib moving target. Cancer Res (2007) 0.88
Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia. J Mol Diagn (2006) 0.88
Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J Biol Chem (2010) 0.88
Adult mastocytosis: a review of the Santo António Hospital 's experience and an evaluation of World Health Organization criteria for the diagnosis of systemic disease. An Bras Dermatol (2014) 0.88
Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material. Diagn Pathol (2007) 0.87
FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem (2009) 0.86
Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V. Haematologica (2013) 0.86
Evaluation of the kinase domain of c-KIT in canine cutaneous mast cell tumors. BMC Cancer (2006) 0.86
Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression. Eur J Haematol (2013) 0.86
KIT with D816 mutations cooperates with CBFB-MYH11 for leukemogenesis in mice. Blood (2011) 0.86
Human mast cell apoptosis is regulated through Bcl-2 and Bcl-XL. J Clin Immunol (2001) 0.85
Gastrointestinal stromal tumours: an update. Sarcoma (1998) 0.85
Selective early production of CCL20, or macrophage inflammatory protein 3alpha, by human mast cells in response to Pseudomonas aeruginosa. Infect Immun (2003) 0.85
CD72 negatively regulates KIT-mediated responses in human mast cells. J Immunol (2010) 0.84
Pathogenesis of RON receptor tyrosine kinase in cancer cells: activation mechanism, functional crosstalk, and signaling addiction. J Biomed Res (2013) 0.84
Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn (2004) 0.84
c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation. J Mol Diagn (2005) 0.83
Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica (2011) 0.83
Effects of nerve growth factor (NGF) and other fibroblast-derived growth factors on immature human mast cells (HMC-1). Immunology (1998) 0.83
Development of mast cells. Proc Jpn Acad Ser B Phys Biol Sci (2007) 0.82
Forsythia fructus inhibits the mast-cell-mediated allergic inflammatory reactions. Inflammation (2003) 0.81
Beginning of personalized medicine in Panama: Molecular and pathological characteristics of gastrointestinal stromal tumors from archival paraffin-embedded tissue. Oncol Lett (2011) 0.81
Identification of nuclear protein targets for six leukemogenic tyrosine kinases governed by post-translational regulation. PLoS One (2012) 0.81
Nerve growth factor-beta induces mast-cell marker expression during in vitro culture of human umbilical cord blood cells. Immunology (2000) 0.80
Oncogenic Kit signals on endolysosomes and endoplasmic reticulum are essential for neoplastic mast cell proliferation. Nat Commun (2014) 0.80
A subset of colorectal carcinomas express c-KIT protein independently of BRAF and/or KRAS activation. Virchows Arch (2007) 0.80
"Occult" mastocytosis with activating c-kit point mutation evolving into systemic mastocytosis associated with plasma cell myeloma and secondary amyloidosis. J Clin Pathol (2006) 0.79
Generation and characterization of novel canine malignant mast cell line CL1. Vet Immunol Immunopathol (2008) 0.78
Amelanotic Anorectal Malignant Melanoma: Case Report with Immunohistochemical Study and Literature Review. Case Rep Oncol (2009) 0.78
Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia (2015) 0.78
The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V. Oncogene (2014) 0.78
KinMutBase, a database of human disease-causing protein kinase mutations. Nucleic Acids Res (2000) 0.77
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia. Nat Rev Cancer (2016) 0.77
c-KIT expression enhances the leukemogenic potential of 32D cells. J Clin Invest (1995) 0.77
A transforming mutation enhances the activity of the c-Kit soluble tyrosine kinase domain. Biochem J (1999) 0.77
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology (1973) 127.36
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol (1977) 41.93
The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science (1988) 35.59
Signal transduction by receptors with tyrosine kinase activity. Cell (1990) 22.72
SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science (1991) 12.93
Growth factor receptor tyrosine kinases. Annu Rev Biochem (1988) 8.67
Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J (1987) 7.32
The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell (1988) 7.10
Hereditary anemias of the mouse: a review for geneticists. Adv Genet (1979) 6.91
The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature (1988) 6.35
Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell (1990) 5.06
The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell (1990) 4.91
A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature (1986) 4.90
Identification of a ligand for the c-kit proto-oncogene. Cell (1990) 4.04
Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell (1990) 3.98
Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver--conditioned medium. Cell (1990) 3.66
Expression and function of c-kit in hemopoietic progenitor cells. J Exp Med (1991) 3.48
Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res (1988) 3.47
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice. Genes Dev (1989) 3.29
Mast cell growth factor maps near the steel locus on mouse chromosome 10 and is deleted in a number of steel alleles. Cell (1990) 2.95
Primary structure and functional expression of rat and human stem cell factor DNAs. Cell (1990) 2.88
Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol (1989) 2.64
A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential. Cell (1988) 2.14
Genetically mast-cell-deficient W/Wv and Sl/Sld mice. Their value for the analysis of the roles of mast cells in biologic responses in vivo. Am J Pathol (1987) 2.05
Candidate ligand for the c-kit transmembrane kinase receptor: KL, a fibroblast derived growth factor stimulates mast cells and erythroid progenitors. EMBO J (1990) 1.94
Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype. Cell (1988) 1.91
The Steel/W transduction pathway: kit autophosphorylation and its association with a unique subset of cytoplasmic signaling proteins is induced by the Steel factor. Mol Cell Biol (1991) 1.76
Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol (1991) 1.65
Signal transduction by normal isoforms and W mutant variants of the Kit receptor tyrosine kinase. EMBO J (1991) 1.58
Selective growth response to IL-3 of a human leukaemic cell line with megakaryoblastic features. Br J Haematol (1988) 1.55
c-kit protein, a transmembrane kinase: identification in tissues and characterization. Mol Cell Biol (1988) 1.47
Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: functional properties and composite antigenic profile. Blood (1991) 1.45
Monoclonal antibody YB5.B8 identifies the human c-kit protein product. Blood (1991) 1.40
Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood (1991) 1.35
Development of human mast cells from umbilical cord blood cells by recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A (1993) 1.30
Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors. Cancer Res (1991) 1.28
Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood (1991) 1.28
Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood (1991) 1.24
Characterization of Ws mutant allele of rats: a 12-base deletion in tyrosine kinase domain of c-kit gene. Blood (1991) 1.14
Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res (1991) 1.13
Development of human mast cells in vitro. Proc Natl Acad Sci U S A (1989) 1.13
Mast cell number in the skin of heterozygotes reflects the molecular nature of c-kit mutation. Blood (1993) 1.03
c-kit mRNA expression in human and murine hematopoietic cell lines. Oncogene (1989) 0.99
IL-4 regulates c-kit proto-oncogene product expression in human mast and myeloid progenitor cells. J Immunol (1991) 0.98
Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line. J Biol Chem (1991) 0.96
The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia (1989) 0.95
Genomic organization of the human c-kit gene: evolution of the receptor tyrosine kinase subclass III. Oncogene (1992) 0.94
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product. Blood (1991) 0.93
Effects of recombinant human stem cell factor (SCF) on the growth of human progenitor cells in vitro. J Cell Physiol (1991) 0.91
Basophil and mast cell lineages in vitro and in vivo. Blood (1992) 0.89
Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood (1992) 0.84
Development of a lethal mast cell disease in mice reconstituted with bone marrow cells expressing the v-erbB oncogene. Blood (1992) 0.81
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity (1999) 7.90
Transducing fragments in generalized transduction by phage P1. I. Molecular origin of the fragments. J Mol Biol (1965) 7.72
Prophage P1, and extrachromosomal replication unit. Cold Spring Harb Symp Quant Biol (1968) 4.75
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Silencing factors participate in DNA repair and recombination in Saccharomyces cerevisiae. Nature (1997) 4.57
Genome sequence of an industrial microorganism Streptomyces avermitilis: deducing the ability of producing secondary metabolites. Proc Natl Acad Sci U S A (2001) 4.56
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation (2001) 4.01
Limb and skin abnormalities in mice lacking IKKalpha. Science (1999) 3.85
Bloom's and Werner's syndrome genes suppress hyperrecombination in yeast sgs1 mutant: implication for genomic instability in human diseases. Proc Natl Acad Sci U S A (1998) 3.14
Relation of GIX antigen of thymocytes to envelope glycoprotein of murine leukemia virus. J Exp Med (1975) 3.06
The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell (2001) 2.97
Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest (2000) 2.96
Epidemiology of anaphylaxis in Olmsted County: A population-based study. J Allergy Clin Immunol (1999) 2.95
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother (1994) 2.76
Experimental investigation of geologically produced antineutrinos with KamLAND. Nature (2005) 2.75
Chromatographic separation and antigenic analysis of proteins of the oncornaviruses. V. Identification of a new murine viral protein, p15(E). J Virol (1975) 2.72
RecQ DNA helicase is a suppressor of illegitimate recombination in Escherichia coli. Proc Natl Acad Sci U S A (1997) 2.51
Purification and characterization of DNA topoisomerase IV in Escherichia coli. J Biol Chem (1992) 2.50
Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc Natl Acad Sci U S A (1998) 2.48
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res (2006) 2.41
Submucosal endoscopic tumor resection for subepithelial tumors in the esophagus and cardia. Endoscopy (2012) 2.32
The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J Exp Med (1999) 2.32
Fractionated stereotactic radiotherapy for choroidal melanoma. Radiother Oncol (1997) 2.29
Hyperglycemia causes oxidative stress in pancreatic beta-cells of GK rats, a model of type 2 diabetes. Diabetes (1999) 2.19
Age-related changes in cell surface antigens of preleukemic AKR thymocytes. J Exp Med (1976) 2.15
Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10
Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine. Blood (1992) 2.06
Regulation of endothelial cell motility by complexes of tetraspan molecules CD81/TAPA-1 and CD151/PETA-3 with alpha3 beta1 integrin localized at endothelial lateral junctions. J Cell Biol (1998) 2.06
A sharp peak of the zero-temperature penetration depth at optimal composition in BaFe2(As(1-x)P(x))2. Science (2012) 2.05
Production of 'hybrid' antibiotics by genetic engineering. Nature (1985) 2.04
High dose rate brachytherapy for carcinoma of the uterine cervix: comparison of two different fractionation regimens. Int J Radiat Oncol Biol Phys (1995) 2.02
Autosomal dominant moyamoya disease maps to chromosome 17q25.3. Neurology (2008) 2.00
Illegitimate recombination mediated in vitro by DNA gyrase of Escherichia coli: structure of recombinant DNA molecules. Proc Natl Acad Sci U S A (1982) 1.97
Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion (2001) 1.97
Biological expression of antigenic determinants of murine leukemia virus proteins gp69-71 and p30. J Virol (1974) 1.95
Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene (1988) 1.95
Augmentation of postnatal neovascularization with autologous bone marrow transplantation. Circulation (2001) 1.92
Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol (1998) 1.91
In vitro study of illegitimate recombination: involvement of DNA gyrase. Cold Spring Harb Symp Quant Biol (1981) 1.90
Diversity of immunodominant 56-kDa type-specific antigen (TSA) of Rickettsia tsutsugamushi. Sequence and comparative analyses of the genes encoding TSA homologues from four antigenic variants. J Biol Chem (1992) 1.87
Characterization of a molecularly cloned retroviral sequence associated with Fv-4 resistance. J Virol (1985) 1.87
The rubble-pile asteroid Itokawa as observed by Hayabusa. Science (2006) 1.87
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. Proc Natl Acad Sci U S A (1980) 1.86
The use of alkaline phosphatase-conjugated anti-immunoglobulin with immunoblots for determining the specificity of monoclonal antibodies to protein mixtures. Methods Enzymol (1986) 1.86
Ascorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia (2009) 1.84
Immunofluorescent staining for mast cells in idiopathic pulmonary fibrosis: quantification and evidence for extracellular release of mast cell tryptase. Mayo Clin Proc (1992) 1.77
Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol (1987) 1.76
IkappaB kinase alpha is essential for mature B cell development and function. J Exp Med (2001) 1.76
Application of the nitrocellulose transfer technique and alkaline phosphatase conjugated anti-immunoglobulin for determination of the specificity of monoclonal antibodies to protein mixtures. J Immunol Methods (1982) 1.76
bcl-2 deficiency in mice leads to pleiotropic abnormalities: accelerated lymphoid cell death in thymus and spleen, polycystic kidney, hair hypopigmentation, and distorted small intestine. Cancer Res (1995) 1.75
Localization of the transmembrane 4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: comparison with CD9, CD63, and alpha5beta1 integrin. J Histochem Cytochem (1997) 1.73
Quartz crystal microbalance for the detection of microgram quantities of human serum albumin: relationship between the frequency change and the mass of protein adsorbed. Anal Chem (1993) 1.73
Phenotypic characterization of the human mast-cell line HMC-1. Scand J Immunol (1994) 1.73
Prevalence of mitochondrial gene mutations among hearing impaired patients. J Med Genet (2000) 1.71
Illegitimate recombination mediated by calf thymus DNA topoisomerase II in vitro. Proc Natl Acad Sci U S A (1988) 1.70
Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc Natl Acad Sci U S A (1989) 1.69
Genetic mapping, cloning and physiological aspects of the glucose kinase gene of Streptomyces coelicolor. Mol Gen Genet (1984) 1.67
Prevalence of K329E mutation in medium-chain acyl-CoA dehydrogenase gene determined from Guthrie cards. Lancet (1991) 1.66
Tissue-specific suppressor T cells involved in self-tolerance are activated extrathymically by self-antigens. Immunology (1994) 1.65
Involvement of DNA-dependent RNA polymerase in a recA-independent pathway of genetic recombination in Escheria coli. Proc Natl Acad Sci U S A (1977) 1.63
Inflammatory pseudotumor of the liver: case report and review of the literature. J Pediatr Surg (2001) 1.61
Cloning and sequencing of the gene (tsg56) encoding a type-specific antigen from Rickettsia tsutsugamushi. Gene (1990) 1.60
Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol (1995) 1.59
New mutant and congenic mouse stocks expressing the murine leukemia virus-associated thymocyte surface antigen GIX. J Exp Med (1975) 1.59
Phlebosclerosis of the colon with positive anti-centromere antibody. Intern Med (1999) 1.55
A platelet tetraspanin superfamily member, CD151, is required for regulation of thrombus growth and stability in vivo. J Thromb Haemost (2009) 1.55
Transcription promotes recA-independent recombination mediated by DNA-dependent RNA polymerase in Escherichia coli. Proc Natl Acad Sci U S A (1979) 1.54
Effects of mutations of RAD50, RAD51, RAD52, and related genes on illegitimate recombination in Saccharomyces cerevisiae. Genetics (1996) 1.52
On the role of recA gene product in genetic recombination: an analysis by in vitro packaging of recombinant DNA molecules formed in the absence of protein synthesis. Mol Gen Genet (1978) 1.52
A unique sequence related to the ecotropic murine leukemia virus is associated with the Fv-4 resistance gene. Proc Natl Acad Sci U S A (1984) 1.51
Molecular analysis of zebrafish photolyase/cryptochrome family: two types of cryptochromes present in zebrafish. Genes Cells (2000) 1.50
Targeted disruption of ATF4 discloses its essential role in the formation of eye lens fibres. Genes Cells (1998) 1.50
Diagnosis of chronic liver disease from liver scintiscans by fuzzy reasoning. J Nucl Med (1995) 1.50
Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid (1993) 1.49
The relationship between disturbed transit and dilated bowel, and manometric findings of dilated bowel in patients with duodenal atresia and stenosis. J Pediatr Surg (1997) 1.49
Preclinical Cushing's syndrome due to adrenocorticotropin-independent bilateral adrenocortical macronodular hyperplasia with concurrent excess of gluco- and mineralocorticoids. Intern Med (1997) 1.49
Moderate increase of mean daily temperature adversely affects fruit set of Lycopersicon esculentum by disrupting specific physiological processes in male reproductive development. Ann Bot (2006) 1.49
IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol (1994) 1.48
A new allele of the lpr locus, lprcg, that complements the gld gene in induction of lymphadenopathy in the mouse. J Exp Med (1990) 1.48
DNA fragmentation of human infarcted myocardial cells demonstrated by the nick end labeling method and DNA agarose gel electrophoresis. Am J Pathol (1995) 1.48
Transducing fragments in generalized transduction by phage P1. 3. Studies with small phage particles. J Mol Biol (1965) 1.47
Double-strand break repair mediated by DNA end-joining. Genes Cells (1998) 1.47
PETA-3/CD151, a member of the transmembrane 4 superfamily, is localised to the plasma membrane and endocytic system of endothelial cells, associates with multiple integrins and modulates cell function. J Cell Sci (1999) 1.47
Whole-body hybrid PET with 18F-FDG in the staging of non-Hodgkin's lymphoma. J Nucl Med (2001) 1.46
Measurement of neutrino oscillation with KamLAND: evidence of spectral distortion. Phys Rev Lett (2005) 1.46
Cellular expression of murine leukemia virus gp70-related antigen on thymocytes of uninfected mice correlates with Fv-4 gene-controlled resistance to Friend leukemia virus infection. Virology (1983) 1.46
Anatomical, electrophysiological and pigmentary aspects of vision in the bush baby: an interpretative study. Vision Res (1965) 1.46
A new genetically obese-hyperglycemic rat (Wistar fatty). Diabetes (1981) 1.46